|
|
Post by norfoster on Sept 8, 2017 15:56:26 GMT
|
|
|
|
Post by JHam on Jul 31, 2018 6:19:55 GMT
Is anyone holding this stock? It's another one on my radar. It has been beaten to a pulp the past year, losing almost 50% of it's value due to halting of a trial with a drug for Crohn's that they had invested $1.6B in, and the acquisition of two companies. The market fear seems to be pretty overblown since they still have some drugs bringing in huge revenue and 10 upcoming drugs with blockbuster potential in the pipeline. Recently management has launched a $3B stock buy back program. It was trading at $147 last October. Current share price: $89 Shares 0/s: 725M Market cap: $64B Cash on hand: $4.7B Debt: $20.3B Recent SA article: seekingalpha.com/article/4186435-celgene-fears-overplayed |
|
|
|
Post by lcd on Aug 14, 2018 17:00:51 GMT
JHam,
I just saw this post from you. I have taken small positions in CELG and GILD over the past month. I think both have been beat up a little too much over the past year.
|
|
